Adenocarcinoma Of the GEJ: Gastric or Oesophageal Cancer?

Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 196)

Abstract

According to WHO (2010) adenocarcinomas of the esophagogastric junction (GEJ) are defined as tumors that cross the most proximal extent of the gastric folds regardless of where the bulk of the tumor lies. In addition, these neoplasms are now classified as esophageal cancers by UICC (2010). Recent studies, however, revealed two types of carcinogenesis in the distal oesophagus and at the GEJ, one of intestinal type (about 80 %) and the other of gastric type (about 20 %). These are characterized by marked differences in morphology, tumor stage at diagnosis, and prognosis. Furthermore, both cancer types show different targetable biomarker expression profiles such as Her2 in the intestinal and EGFR in the non-intestinal pathway indicating new therapy options. Due to the fact that carcinomas of the intestinal pathway were typically associated with Barrett’s mucosa which was not the case in the non-intestinal-type tumors, this challenges the paradigm “no goblets no Barrett’s”. Moreover, even the cancer risk of intestinal-type metaplasia has seriously been questioned by a Danish population-based study where Barrett’s mucosa turned out to be only a weak indicator of esophageal and GEJ cancer (1 case in 860 patients years). Thus, two biologically different types of cancer arise at the GEJ—esophageal and gastric type that open distinctive targeted treatment options and also question our current concept about the diagnostics of potential precursor lesions as well as the associated screening and surveillance strategy.

Keywords

Gastric Acid Secretion Her2 Positivity Goblet Cell Metaplasia Gastric Type ToGA Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
  2. Baretton GB, Aust DE (2012) Barrett-ösophagus. Aktueller Stand Pathologe 33:5–16Google Scholar
  3. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. IARC, LyonGoogle Scholar
  4. Brown IS, Whiteman DC, Lauwers GY (2010) Foveolar type dysplasia in Barrett esophagus. Mod Pathol 23:834–843PubMedCrossRefGoogle Scholar
  5. Chandrasoma P, Wijetunge S, DeMeester S, Ma Y, Hagen J, Zamis L, DeMeester T (2012) Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 36:1–7PubMedCrossRefGoogle Scholar
  6. Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M (2011) The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 24(9):1177–1190PubMedCrossRefGoogle Scholar
  7. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298–304PubMedCrossRefGoogle Scholar
  8. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383PubMedCrossRefGoogle Scholar
  9. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797–805PubMedCrossRefGoogle Scholar
  10. Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, Imatani A, Ohara S, Shimosegawa T (2011) Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 46:710–719PubMedCrossRefGoogle Scholar
  11. Kahrilas PJ (2011) The problems with surveillance with Barrett´s esophagus. N Engl J Med 365:1437–1438Google Scholar
  12. Khor TS, Alfaro EE, Ooi EM, Li Y, Srivastava A, Fujita H, Park Y, Kumarasinghe MP, Lauwers GY (2012) Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? Am J Surg Pathol 36:331–342PubMedCrossRefGoogle Scholar
  13. Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Brümmendorf TH, Fiedler W, Bokemeyer C, Izbicki JR, Sauter G (2010) Homogeneous EGFR amplification defines a subset of aggressive Barrett’s adenocarcinomas with poor prognosis. Histopathology 57:418–426PubMedCrossRefGoogle Scholar
  14. Pohl H, Welch G (2005) The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRefGoogle Scholar
  15. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637–650PubMedGoogle Scholar
  16. Siewert JR, Stein HJ, Lordick F (2006) Ösophaguskarzinom. In Siewert JR, Rothmund M, Schumpelick V (eds) Praxis der viszeralchirurgie. Springer, HeidelbergGoogle Scholar
  17. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F (2009) EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 62:970–977PubMedCrossRefGoogle Scholar
  18. Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P (2010) Association of adenocarcinomas of the distal esophagus, “gastroesophageal junction,” and “gastric cardia” with gastric pathology. Am J Surg Pathol 34:1521–1527PubMedCrossRefGoogle Scholar
  19. Wittekind C, Meyer H-J (2010) TNM Klassifikation maligner Tumoren 7. Auflage. Wiley-VHC, Weinheim Google Scholar
  20. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18:546–554PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Institut für Pathologie NordhessenKasselGermany

Personalised recommendations